NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics (OTCBB: BCLI), a developer of adult stem cell technologies and CNS therapeutics, announced today that together with the Hadassah Medical Organization, a successful study initiation/clinical trial kickoff meeting was held on June 6, 2011 at the Hadassah Medical Center and with this meeting the trial is underway. BrainStorm is the first company to receive approval from the Israeli Ministry of Health (MOH) for a differentiated stem cell-based therapy and approval of its Phase I/II clinical trial utilizing its proprietary NurOwn™ treatment for patients with Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's Disease.
